¼¼°èÀÇ PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀå(2025-2029³â)
Global PARP (poly Adp-ribose Polymerase) Inhibitors Market 2025-2029
»óǰÄÚµå : 1756540
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 221 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,422,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,476,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀåÀº 2024-2029³â 195¾ï 3,560¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£ µ¿¾È CAGR 22.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ Æ÷ÇÔÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº PARP ¾ïÁ¦Á¦ÀÇ Àû¿ë È®´ë, ´Ù¾çÇÑ ¾Ï ÀûÀÀÁõ¿¡ ´ëÇÑ Ä¡·áÀÇ ¿ëÀ̼º, ȯÀÚ Áö¿ø ÇÁ·Î±×·¥ÀÇ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2025³â
Á¾·á ¿¬µµ 2029
¿¹Ãø ±â°£ 2025-2029³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³âºñ 18.1%
CAGR 22.5%
Áõ°¡¾× 195¾ï 3,560¸¸ ´Þ·¯

ÀÌ Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü°¡ÀÚÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ ¹× 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î °áÇÕÇÏ¿© ¼öÇàµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼­¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÇâÈÄ ¸î ³â µ¿¾È PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ÇöÀç ÁøÇà ÁßÀÎ ±¤¹üÀ§ÇÑ ¿¬±¸¸¦ ²Å°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ÏÀÇ À¯º´·ü Áõ°¡¿Í Àΰ£ À¯ÀüÀÚ¿¡ ´ëÇÑ »õ·Î¿î ¿¬±¸ ºÐ¾ß´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå »óȲ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦6Àå Á¤¼º ºÐ¼®

Á¦7Àå Five Forces ºÐ¼®

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦9Àå ½ÃÀå ¼¼ºÐÈ­ : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ½ÃÀå ¼¼ºÐÈ­ : ¾à¹° Á¾·ùº°

Á¦11Àå °í°´ »óȲ

Á¦12Àå Áö¿ªº° »óȲ

Á¦13Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå °æÀï ºÐ¼®

Á¦16Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The parp (Poly ADP-Ribose Polymerase) inhibitors market is forecasted to grow by USD 19,535.6 mn during 2024-2029, accelerating at a CAGR of 22.5% during the forecast period. The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanded application of parp inhibitors, ease of administration for treatment of various cancer indications, and increasing patient assistance programs.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 202518.1%
CAGR22.5%
Incremental Value$19,535.6 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's parp (Poly ADP-Ribose Polymerase) inhibitors market is segmented as below:

By Distribution Channel

By End-user

By Drug Class

By Geographical Landscape

This study identifies the extensive ongoing research as one of the prime reasons driving the parp (Poly ADP-Ribose Polymerase) inhibitors market growth during the next few years. Also, growing prevalence of cancer and new research areas in human genes will lead to sizable demand in the market.

The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-Ribose Polymerase) inhibitors market vendors that include AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd.. Also, the parp (Poly ADP-Ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Historic Market Size

6 Qualitative Analysis

7 Five Forces Analysis

8 Market Segmentation by Distribution Channel

9 Market Segmentation by End-user

10 Market Segmentation by Drug Class

11 Customer Landscape

12 Geographic Landscape

13 Drivers, Challenges, and Opportunity/Restraints

14 Competitive Landscape

15 Competitive Analysis

16 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â